Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study

• Published in: American journal of respiratory and critical care medicine Vol. 196; no. 1; p. 29
• Main Authors: Mochizuki, Hiroyuki, Kusuda, Satoshi, Okada, Kenji, Yoshihara, Shigemi, Furuya, Hiroyuki, Simões, Eric A F
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.07.2017
• Subjects: Age; Antiviral Agents - therapeutic use; Asthma; Asthma - prevention & control; Case-Control Studies; Cellular telephones; Child; Child, Preschool; Female; Follow-Up Studies; Food allergies; Health risk assessment; Humans; Immunotherapy; Infant; Infant, Premature; Infections; Male; Monoclonal antibodies; Newborn babies; Palivizumab - therapeutic use; Parents & parenting; Physicians; Premature babies; Prospective Studies; Recurrence; Respiratory Sounds - drug effects; Respiratory syncytial virus; Respiratory Syncytial Virus Infections - prevention & control; Respiratory Syncytial Viruses - drug effects; Treatment Outcome; Viral infections; asthma; palivizumab; monoclonal antibody; respiratory syncytial virus; respiratory infectious diseases

Respiratory syncytial virus (RSV) induces not only infantile recurrent wheezing but also potentially atopic asthma. To test the effect of RSV infection on development of subsequent atopic asthma, we evaluated whether palivizumab, an anti-RSV monoclonal antibody, by preventing severe RSV disease in t...